

SpO<sub>2</sub> normale: P50:97.5%, P10: 94.5%  
59% des enfants au moins 1 épisode de désat > 90% sur 24h  
Durée médiane de l'épisode de de 6 secondes.  
La respiration périodique liée à l'âge semble le facteur principal

# Longitudinal assessment of hemoglobin oxygen saturation in healthy infants during the first 6 months of age

Carl E. Hunt, MD, Michael J. Corwin, MD, George Lister, MD, Debra E. Weese-Mayer, MD, Michael R. Neuman, MD, PhD, Larry Tinsley, MD, Terry M. Baird, MD, Thomas G. Keens, MD, Howard J. Cabral, PhD, MPH, and the Collaborative Home Infant Monitoring Evaluation (CHIME) Study Group

Limitations in home monitoring technology have precluded longitudinal studies of hemoglobin oxygen saturation during unperturbed sleep. The memory monitor used in the Collaborative Home Infant Monitoring Evaluation addresses these limitations. We studied 64 healthy term infants at 2 to 25 weeks of age. We analyzed hemoglobin oxygen saturation by pulse oximetry (SpO<sub>2</sub>), respiratory inductance plethysmography, heart rate, and sleep position during 35,127 epochs automatically recorded during the first 3 minutes of each hour. For each epoch baseline SpO<sub>2</sub> was determined during  $\geq 10$  s of quiet breathing. Acute decreases of at least 10 saturation points and  $< 90\%$  for  $\geq 5$  s were identified, and the lowest SpO<sub>2</sub> was noted. The median baseline SpO<sub>2</sub> was 97.9% and did not change with age or sleep position. The baseline SpO<sub>2</sub> was  $< 90\%$  in at least 1 epoch in 59% of infants and in 0.51% of all epochs. Acute decreases in SpO<sub>2</sub> occurred in 59% of infants; among these, the median number of episodes was 4. The median lowest SpO<sub>2</sub> during an acute decrease was 83% (10th, 90th percentiles 78%, 87%); 79% of acute decreases were associated with periodic breathing, and  $\geq 16\%$  were associated with isolated apnea. With the use of multivariate analyses, the odds of having an acute decrease increased as the number of epochs with periodic breathing increased, and they lessened significantly with age. We conclude that healthy infants generally have baseline SpO<sub>2</sub> levels  $> 95\%$ . The transient acute decreases are correlated with younger age, periodic breathing, and apnea and appear to be part of normal breathing and oxygenation behavior. (J Pediatr 1999;134:580-6)

Postmortem studies of victims of sudden infant death syndrome have identified subtle findings or tissue markers indicative of pre-existing hypoxia in nearly two thirds of subjects.<sup>1</sup> Until recently, limitations in home-based monitoring technology have precluded

CHIME	Collaborative Home Infant Monitoring Evaluation
OR	Odds ratio
SpO <sub>2</sub>	Hemoglobin oxygen saturation by pulse oximetry
RIP	Respiratory inductance plethysmography

recording of hemoglobin oxygen saturation by pulse oximetry during natural unperturbed sleep. The earliest home recordings of SpO<sub>2</sub> in infants<sup>2-4</sup> were generally limited to 1 or 2 overnight recordings per subject. With the use of a state-of-the-art memory monitor with integrated pulse oximeter, transthoracic impedance, and electrocardiography, a recent study in 88 healthy term infants at 2 to 19 weeks of age<sup>5</sup> did provide a more comprehensive assessment of breathing pattern, heart rate, and SpO<sub>2</sub> during sleep in the natural home setting. Despite the expanded scope of these data, howev-

See editorial, p. 541.

From the Department of Pediatrics, Medical College of Ohio, Toledo, Ohio.

The CHIME study is supported by National Institute of Child Health and Human Development HD: 29067, 29071, 28971, 29073, 29060, 29056, and 34625.

Presented in part at the Annual Meeting of the Pediatric Academic Societies, Washington, DC, May 2-6, 1997, and the Fifth International SIDS Conference, Rouen, France, April 20-23, 1998.


Submitted for publication Jan 25, 1999; revisions received Apr 15, 1999, and June 18, 1999; accepted July 1, 1999.

Reprint requests: Carl E. Hunt, MD, Department of Pediatrics, Medical College of Ohio, Toledo, OH 43614-2598.

Copyright © 1999 by Mosby, Inc.

0022-3476/99/\$8.00 + 0 9/21/101362

er, there were 2 major limitations: (1) baseline SpO<sub>2</sub> could not be characterized, because data could only be stored in memory when the recording threshold for apnea or bradycardia was



**Fig 1.** Assessment of 3-minute non-event epoch. This infant is 8 weeks old. See Methods for scoring criteria for each step: Step 1: Determine baseline  $\text{SpO}_2$  ( $\text{SpO}_2$ ): 2 cursor lines mark beginning and end of segment meeting criteria for this baseline  $\text{SpO}_2$  of 93%. Step 2: Identify acute decreases in  $\text{SpO}_2$ ; there are 3 acute decreases in this epoch. Each decrease is then scored for duration  $<90\%$  and  $<80\%$ , lowest  $\text{SpO}_2$ , and longest respiratory pause associated with decrease. Lowest values for these 3 acute decreases are 75%, 80%, and 82%, respectively. Step 3: Identify all apneas  $>4$  s; there are 6 apneas  $>4$  s in this epoch, numbered as 1 through 6. Total number of apneas  $>4$  s is counted and the total duration recorded with scoring tool. Step 4: Identify periodic breathing: 2 cursors mark periodic breathing episode of 78 s. Step 5: Identify sleep position for baseline  $\text{SpO}_2$  and acute decreases in  $\text{SpO}_2$ . Infant is sleeping on side during this epoch. *Oxi-P*, Pulse rate from oximeter; *RC*, signal proportional to thoracic (rib cage) cross-sectional area; *AB*, signal proportional to abdominal cross-sectional area; *Sum*, weighted sum of *RC* and *AB*, proportional to tidal volume.

reached, and (2) there were substantial gaps during which  $\text{SpO}_2$  could not be ascertained, because these healthy infants triggered an event recording approximately 2 times per week only.

The memory monitor developed for the Collaborative Home Infant Monitoring Evaluation study<sup>6</sup> was designed to store automatically all physiologic data during the first 3 minutes of each hour, thus providing an opportunity to observe  $\text{SpO}_2$  during previously inaccessible periods. The specific aims of this study in healthy term infants during unperturbed home sleep were to (1) describe  $\text{SpO}_2$  in the first 25 post-natal weeks and (2) assess the relation-

ships among  $\text{SpO}_2$ , breathing pattern, heart rate, and sleep position.

## METHODS

The healthy term infants enrolled in the CHIME study were born at 38 to 42 weeks' gestation. All were appropriate for gestational age, were normal at delivery, were discharged with the mother, and were  $\leq 30$  days old at enrollment. The exclusion criteria included any acute illness and a family history of sudden infant death syndrome. Written informed consent was obtained for each infant, and the Institu-

tional Review Board at each site approved the study.

Among the 214 healthy term infants enrolled in May 1994 to July 1997, 67 infants used the monitor  $\geq 50$  h/mo for  $\geq 3$  months. This criterion ensured that each subject contributed longitudinal data over the full age range of 2 to 25 weeks. Three infants were excluded for technical reasons or acute respiratory illness requiring hospitalization. The remaining 64 healthy infants are the subject of this report.

### Physiologic Recordings

The CHIME monitor (NIMS, Inc, Miami, Fla) includes respiratory induc-

**Table** Characteristics of the mothers of healthy term infants and infant characteristics compared with the total CHIME group of healthy term infants

Group characteristics	Study group ( $\geq 50$ h/mo for $\geq 3$ mo) (n = 64)	Comparison (insufficient monitor use) (n = 150)
<b>Maternal characteristics</b>		
Age*	31.8 (5.7)	28.8 (6.1)
Education*	15.9 (2.9)	14.4 (2.7)
Race/ethnic group*		
% White	64.1	47.3
% Black	3.1	21.6
% Hispanic	7.8	8.1
% Asian	7.8	8.1
% Other	17.2	14.9
% Married*	93.8	81.0
Parity		
% 1	49.	42.
% 2	29.	28.
% 3+	15.	17.
% Pregnancy cigarette use	9.4	18.2
% Pregnancy alcohol use	21.9	24.3
<b>Infant characteristics</b>		
% Male	50.0	58.9
Gestational age at birth	39.5 (1.0)	39.6 (1.0)
Birth weight	3320 (310)	3323 (291)
Age at monitor start (d)	16.3 (9.9)	17.4 (9.4)
Except as indicated, the maternal characteristics did not differ. None of the differences in infant characteristics was statistically significant (SD).		
* $P < .02$ .		

tance plethysmography, an electrocardiographic monitor and cardiotachometer, an Ohmeda Minx pulse oximeter (Ohmeda Corp, Liberty Center, NJ), a position sensor placed on the diaper over the lumbar region, a data acquisition computer, and a 120-Mb removable memory cartridge.<sup>6,7</sup> The oximeter uses a 3-second moving average of SpO<sub>2</sub> that updates once per second. Reusable probes (Ohmeda SoftProbe) were placed on a foot and repositioned every 4 to 8 hours. Each family was asked to use the monitor during nocturnal sleep until the infant was 6 months of age. Because most monitor use occurred between 10:00 PM and 7:00 AM and at 2 to 25 weeks, we limited our analyses to these hours and ages.

The CHIME monitor was programmed to store continuous waveforms for all physiologic variables dur-

ing the first 3 minutes of each hour and all events reaching the recording threshold for apnea (16 s) or bradycardia (heart rate <80 bpm for  $\geq 5$  s). For each event all waveforms were recorded for 75 seconds before and 30 s after resolution of the event.<sup>6</sup> Research staff called each family weekly and conducted a scripted interview that included acute illness information.

Three technicians analyzed the 3-minute epochs with a software tool programmed to display only the 3-minute epochs.<sup>6</sup> The physiologic montage (Fig 1) included SpO<sub>2</sub> and the pulse signal from the oximeter, 3 channels from the respiratory inductance plethysmography bands (abdominal and thoracic inductance, sum), electrocardiography and heart rate, and sleep position. A reliable pulse oximetry signal contained pulses that coincided

with the QRS segment on the electrocardiogram for the entire duration of the event. Only periods with a reliable pulse signal that was free of movement artifact were used in scoring SpO<sub>2</sub>. Variables were reported as the proportion of 3-minute epochs that met a specified criterion or as the total number of seconds during which specific criteria were met, thus permitting inclusion of multiple occurrences during a single epoch (Fig 1). All changes in SpO<sub>2</sub> that began during or within 10 s of a threshold violation were scored.

Baseline SpO<sub>2</sub> was the longest interval  $\geq 10$  s in duration that met the following conditions: regular respiratory rate and amplitude, good oximeter waveform, no movement artifact, and  $\geq 15$  s after any movement, sigh, or respiratory pause  $\geq 5$  s. The baseline SpO<sub>2</sub> was determined by calculating the mean of the saturation values (1 sample/s) during this segment.

Acute decreases in SpO<sub>2</sub> were defined as a decrease of  $\geq 10\%$  from a stable preceding baseline interval (ie, from 93% to 83%) that was sustained <90% for  $\geq 5$  s. For each acute decrease in SpO<sub>2</sub>, 4 variables were stored: duration of SpO<sub>2</sub> <90% and <80%, lowest SpO<sub>2</sub> reached, and the longest respiratory pause associated with the acute decrease.


For each 3-minute nonevent epoch, the total duration of each apnea  $\geq 5$  s was measured and stored. For purposes of this study, the sum channel was used to identify and measure the duration of each apnea (Fig 1). Apnea duration was scored from peak-to-peak. The duration of periodic breathing within each epoch was measured. Periodic breathing was defined as a sequence of  $\geq 3$  episodes of apnea >3 s in duration and separated by <20 s of normal respiration. In many instances the beginning or end of the periodic breathing episode did not occur within the epoch. For each second during the 3-minute epoch, the software tool sampled and stored infant position as prone, side, or supine.

## Statistics

In bivariate analyses comparing 2 groups of children (eg, with and without  $\geq 1$  low baseline SaO<sub>2</sub> episode), we used chi-squared tests for categorical variables and independent sample *t* tests for continuous data. We used a generalized linear mixed model (PROC GLIMMIX, SAS Institute, Inc, Cary, NC) to assess the association between the likelihood of having an acute decrease during a particular week and the time-dependent variables age, proportion of time in each position, number of epochs with periodic breathing, and illness.<sup>8</sup> This approach accounts for irregularly spaced and randomly missing data and repeated measures within the same subject. Results with *P* values  $< .05$  are described as statistically significant.

## RESULTS

The 64 infants in this study were compared with the 150 healthy term infants not included (Table). Mothers of infants in the study group were more likely to be older, white, married, and more highly educated. Infant characteristics, however, were similar in the 2 groups. Among 41,821 3-minute epochs, 3064 (7.3%) were uninterpretable because of movement artifact, and 3630 (8.7%) epochs were excluded because there was no oximeter signal, leaving 35,127 epochs (1756 hours) for analysis. The distribution of epochs by sleep position was 65% supine, 10% side, and 25% prone. During 30 epochs (0.09%) the apnea recording threshold ( $\geq 16$  s) had been met. Ten of these were false events,<sup>6,8</sup> and 20 were judged to be true apnea of 16 to 22 s in duration without any bradycardia or SpO<sub>2</sub> value  $< 90\%$  for  $\geq 5$  s. The median time assessed per infant was 25.4 hours (507 epochs), and the range was 7.9 to 49.9 hours (158 to 999 epochs, respectively). The median time assessed each week was 80.4 hours (1609 epochs). The absolute number of epochs per week ranged from 983 to



**Fig 2.** Median baseline SaO<sub>2</sub> (SpO<sub>2</sub>) for each postnatal week at 2 to 25 weeks of age. Variations in SpO<sub>2</sub> occurring with increasing age are not significant.

1970 in weeks 24 and 10, respectively, and was higher during weeks 9 to 12 (range 1763 to 1970) than either the first 4 weeks (998 to 1656) or the last 4 weeks (983 to 1192).


Baseline SpO<sub>2</sub> was identified in 33,801 (96.2%) of the epochs. The most common reasons for being unable to measure baseline saturation were unstable breathing pattern and movement. The median and 10th percentile for baseline SpO<sub>2</sub> were 97.9% and 95.2%, respectively (Fig 2), but there were 203 epochs (0.6%) with a baseline SpO<sub>2</sub>  $< 90\%$ , and 38 (59%) infants had at least 1 epoch with a baseline SpO<sub>2</sub>  $< 90\%$ . Among these 38 infants, 25 had 1 to 4 low baselines, 7 had 5 to 9 episodes, and 6 had a range of 11 to 26 episodes. No change occurred in baseline SpO<sub>2</sub> as infant age increased from 2 to 25 weeks. The number of epochs containing a low baseline SpO<sub>2</sub> was not associated with infant age, sleep position, or the presence of periodic breathing.

Acute decreases in SpO<sub>2</sub> occurred in 178 (0.51%) of epochs. The total number of acute decreases was 308, and the total number of seconds of SpO<sub>2</sub>  $< 90\%$  during acute decreases was 2362 s

(1.34 s/h). At least 1 acute decrease was observed in 38 (59%) infants; the median number of events per infant was 4 (range 1 to 71), and the 25th and 75th percentiles were 2 and 7 events, respectively. In the epochs with acute decreases, the mean baseline SpO<sub>2</sub> was 96.7% (SD 2.5). The median lowest SpO<sub>2</sub> was 83% (10th, 90th percentiles 78%, 87%). The median time  $< 90\%$  was 6.3 s (6.0, 9.8), and the median time  $< 80\%$  was 3.5 s (1.9, 6.0). The frequency of acute decreases was 1.8 s/h in supine, 0.4 in side, and 0.6 in the prone sleep positions.

Infants with  $\geq 1$  low baseline SpO<sub>2</sub> were more likely to have at least 1 acute decrease in SpO<sub>2</sub> (odds ratio 1.9, 95% CI 1.1, 3.6, *P*  $< .05$ ); 95% of acute decreases were associated with a respiratory pause, 79% during periodic breathing (Fig 1), and at least another 16% during single apneas. Because most of the remaining acute decreases occurred at the beginning of an epoch, apnea just before the epoch cannot be excluded as a precipitating factor.

The number of seconds per hour of SpO<sub>2</sub>  $< 90\%$  during acute decreases declined with age (Fig 3). Although the relative proportion of acute decreases



**Fig 3.** Number of seconds with  $\text{SaO}_2$  ( $\text{SpO}_2$ )  $< 90\%$  during acute decrease, expressed per hour by presence of periodic breathing and by week of age.

occurring during nonperiodic apnea did not change with age, the amount of periodic breathing decreased with age (5.4%, 3.6%, and 1.5% at 2, 12, and 22 weeks, respectively) and was less when prone (1.6% of epochs) compared with the side or supine sleep positions (3.3% of epochs). **The number of seconds per hour of periodic breathing was 58 in prone versus 118 and 120 s in side and supine, respectively.**

With the use of the generalized linear mixed model,<sup>9</sup> infants were more likely to have an acute decrease during a week of monitoring if they were younger (OR per week younger = 0.95, 95th percentile CI 0.90, 0.99) or if they had more epochs with periodic breathing (OR per epoch periodic breathing = 1.1, 95th percentile CI: 1.05, 1.14,  $P = .0001$ ). The odds, for example, of having an acute decrease during the seventh week of life are 30% less than during the third week of life (95th percentile CI 0.65 to 0.72). In a similar manner, the odds of having an acute decrease during a week including 5 epochs with periodic breathing are 50% higher than during a week with no epochs containing periodic breathing (OR 1.55, 95th percentile CI: 1.48, 1.61). Although there was no

relationship between sleep position and acute decreases in  $\text{SpO}_2$  by multivariate analysis, the acute decreases occurred significantly more often during nonprone sleep, because periodic breathing occurred significantly more often during nonprone sleep.

## DISCUSSION

The features of the CHIME monitor enabled recording of 35,127 3-minute observations unaffected by monitor alarms or other systematic perturbations and have yielded new insights into baseline and acute decreases in  $\text{SpO}_2$ . Infants with  $\geq 1$  low baseline  $\text{SpO}_2$  were more likely to have  $\geq 1$  acute decrease in  $\text{SpO}_2$ . The acute decreases improve with age and are primarily associated with periodic breathing; periodic breathing is more common in nonprone sleeping positions. **Because the periodic breathing, acute decreases in  $\text{SpO}_2$ , and low baseline  $\text{SpO}_2$  occurred in healthy term infants without adverse consequences, these results do not represent an advantage of prone sleeping but rather represent an expanded understanding of the normative range of these respiratory and oxygenation behaviors.**

These results expand the normative data derived from the first study of longitudinal oxygen saturation with home memory monitoring.<sup>5</sup> Although it was not possible to characterize baseline  $\text{SpO}_2$  in that study, periodic decreases to levels as low as 72% were observed with periodic breathing, and the lowest weekly value was always  $< 82\%$ . **The median duration of these acute decreases in  $\text{SpO}_2$  to  $< 90\%$  was only 5 s, but the range was wide (1 to 183 s), and 9.6% of episodes were  $> 10$  s.**

The CHIME monitor enabled us to obtain an average of 40 observations per week, equivalent to  $\geq 120$  minutes of physiologic data per week. These 3-minute epochs are more representative of unperturbed sleep than the previous "event"-based observations potentially influenced by the circumstance(s) triggering the "event" recording. We selected 3-minute epochs as a reasonable compromise between longer or more frequent automatic epochs and too-frequent filling of cartridge memory. Addition of the sleep position sensor has yielded new insights into the interrelationships among  $\text{SpO}_2$ , breathing pattern, and heart rate. There was significantly less periodic breathing in the prone position compared with that in side and supine sleeping. This was previously observed in overnight polysomnograms in term infants<sup>9</sup> but not in preterm infants during daytime recordings.<sup>10</sup>

Because of limited correlation between low baseline  $\text{SpO}_2$  and acute decreases in  $\text{SpO}_2$ , we considered the possibility that the low baseline values were artifactual. Falsely low  $\text{SpO}_2$  levels caused by movement artifact interfering with pulse detection are common, but all discernable movement-related artifacts were excluded at the time of epoch scoring. However, joint flexion might decrease arterial pulse pressure below a threshold level,<sup>11,12</sup> artifactually low values have been observed with marked venous pulsations,<sup>13</sup> and optical shunting or bridging<sup>12,15</sup> can occur. The effect of

bridging depends on whether the infrared or the red emitter is malpositioned, and the effect is brand-specific. With Ohmeda oximeters and probes, bridging can be the cause of SpO<sub>2</sub> decreases of 2% to 4% but should result in a default reading of "probe off" before reaching the magnitude of decrease (<90%) required for scoring as a low baseline (personal communication, Jonas Pologe, Manager of Research, Ohmeda Corp). Although we cannot exclude artifact, it is also possible that these low baseline SpO<sub>2</sub> values are real and indicative of the lower range of values occurring in healthy term infants during early infancy.

In general, the Ohmeda oximeter yields SpO<sub>2</sub> values having a mean difference of 1.61% less ( $P < .001$ ) compared with the Nellcor oximeter.<sup>15-17</sup> Allowing for these small but systematic differences, our results are generally consistent with previous normative studies.<sup>2-5,18,19</sup> Although our median baseline SpO<sub>2</sub> of 97.9% is somewhat higher than in other studies with Ohmeda oximeters, our criteria for baselines were strictly defined to avoid any movement artifact or proximity to apnea or sighs and should thus be more representative of true baseline values. **Because mean respiratory rates tended to be higher when baseline SpO<sub>2</sub> was <95% compared with >95%, our higher baseline values are not related to relative hyperventilation.**

The earliest studies in term healthy infants were based on brief cross-sectional assessments of home-based SpO<sub>2</sub>. With the use of the Nellcor pulse oximeter at a median age of 39 days, the baseline range for SpO<sub>2</sub> was 97% to 100% (median 99.8%) during regular breathing.<sup>2,18,19</sup> At median ages of 4 and 17 days,<sup>3</sup> the baseline range for SpO<sub>2</sub> was 92% to 100% (median 97.6%) and 86.6% to 100% (median 98.0%), respectively. **Episodic decreases to ≤80% for ≥4 s occurred, were associated with periodic breathing, had a peak frequency during the second week of age,<sup>2</sup> and were rare by 6 weeks**

of age, even though shorter episodes <4 s persisted at a median frequency of 0.7 episodes per hour. At 2 to 11 months<sup>4</sup> mean levels during quiet sleep were 94% to 95% when the infants were both supine and prone and were not affected by upper respiratory illness.

In summary, these longitudinal observations of SpO<sub>2</sub> identify relevant correlations with age, apnea, and sleep position. These results will provide a frame of reference for event recordings in individual infants and in groups of infants at risk for sudden infant death syndrome.

*The participants in the CHIME Study Group include:*

*Clinical sites:*

*Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio*

*MetroHealth Medical Center:*

*Terry M. Baird\* (currently at the University of Utah School of Medicine, Salt Lake City, Utah)*

*Rainbow Babies and Children's Hospital:*

*Richard J. Martin*

*Lee J. Brooks (currently at The Children's Regional Hospital at Cooper, Robert Wood Johnson School of Medicine/UMDNJ, Camden, NJ)*

*Roberta O'Bell\*\**

*Department of Pediatrics, Medical College of Ohio, Toledo Hospital and St. Vincent Mercy Medical Center, Toledo, Ohio:*

*Carl E. Hunt\**

*David R. Hufford*

*Mary Ann Oess\*\**

*Department of Pediatrics, Division of Respiratory Medicine, Rush Medical College of Rush University, Chicago, Illinois: Rush Children's Hospital at Rush-Presbyterian-St. Luke's Medical Center:*

*Debra E. Weese-Mayer\**

*Jean M. Silvestri*

*Sheilah M. Smok-Pearsall\*\**

*Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii: Kapiolani Medical Center for Women and Children:*

*David H. Crowell\**

*Larry E. Tinsley,*

*Linda E. Kapuniai\*\**

*Department of Pediatrics and Neonatology, USC School of Medicine, Los Angeles, California:*

*Los Angeles County & USC Medical Center, Women's and Children's Hospital:*

*Toke T. Hoppenbrouers\**

*Rangasamy Ramanathan*

*Paula Palmer\*\**

*Children's Hospital of Los Angeles:*

*Thomas G. Keens*

*Sally L. Davidson Ward*

*Daisy B. Bolduc, Technical Coordinator*

*Clinical Trials Operations Center:*

*Department of Obstetrics and Gynecology, Case Western University School of Medicine and MetroHealth Medical Center, Cleveland, Ohio:*

*Michael R. Neuman\* (currently at the University of Memphis, Memphis, Tennessee)*

*Rebecca S. Mendenhall\*\**

*Data Coordinating and Analysis Center:*

*Departments of Pediatrics and Epidemiology and Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts:*

*Michael J. Corwin\**

*Theodore Colton*

*Sharon M. Bak\*\**

*Mark Peucker, Technical Coordinator*

*Howard Golub, Physiologic Data*

*Biostatistician*

*Susan C. Schafer, Clinical Trials*

*Coordinator*

*Steering Committee Chairman:*

*Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut:*

*George Lister*

*National Institutes of Health (NIH):*

*Pregnancy and Perinatology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, Maryland:*

*Marian Willinger*

*\* Principal Investigator*

*\*\* Study Coordinator*

## REFERENCES

1. Hunt CE. Sudden Infant Death Syndrome. In: Beckerman RC, Brouillette RT, Hunt CE, editors. Respiratory control disorders in infants and children. Baltimore: Williams & Wilkins; 1992. p. 190-211.
2. Stebbens VA, Poets CF, Alexander JR, Arrowsmith WA, Southall DP. Oxygen saturation and breathing patterns in infancy. I. Full term infants in the second month of life. Arch Dis Child 1991;66:569-73.
3. Poets CF, Stebbens VA, Lang JA, O'Brien LM, Boon AW, Southall DP. Arterial oxygen saturation in healthy term infants. Eur J Pediatr 1996;155: 219-23.
4. Levene S, SA McKenzie. Transcutaneous oxygen saturation in sleeping infants: prone and supine. Arch Dis Child 1990;65:524-6.

5. Hunt CE, Hufford DR, Bourguignon C, Oess MA. Home documented monitoring of cardiorespiratory pattern and oxygen saturation in healthy infants. *Pediatr Res* 1996;39:216-22.
6. Corwin MJ, Lister G, Silvestri JM, Peucker M, Brooks LJ, Davidson Ward SL, et al, and the Collaborative Home Infant Monitoring Evaluation (CHIME) Study Group. Agreement among raters in assessment of physiologic waveforms recorded by a cardiorespiratory monitor for home use. *Pediatr Res* 1998;44:682-90.
7. Adams JA, Zabaleta IA, Sackner MA. Hypoxic events in spontaneously re-breathing premature infants: etiologic basis. *Pediatr Res* 1997;42:463-71.
8. Wolfinger R, O'Connell M. Generalized linear mixed models: a pseudolikelihood approach. *J Stat Comput Sim* 1993;48:233-43.
9. Skadberg BT, Markestad T. Behaviour and physiological responses during prone and supine sleep in early infancy. *Arch Dis Child* 1997;76:320-4.
10. Goto K, Mirmiran M, Adams MM, Longford RV, Baldwin RB, Boeddiker MA, et al. More awakenings and heart rate variability during supine sleep in preterm infants. *Pediatrics* 1999;103:603-9.
11. Poets CF, DP Southall. Noninvasive monitoring of oxygenation in infants and children: practical considerations and areas of concern. *Pediatrics* 1994;94:737-46.
12. Barker SJ, Shah NK. The effects of motion on the performance of pulse oximeters in volunteers (revised publication). *Anesthesiology* 1997;86:101-8.
13. Sami HM, Kleinman BS, Lonchyna VA. Central venous pulsations associated with a falsely low oxygen saturation measured by pulse oximetry. *J Clin Monit Comput* 1991;7:309-12.
14. Lindberg LG, Lennmarken C, Vegfors M. Pulse oximetry: clinical implications and recent technical developments. *Acta Anesthesiol Scand* 1995;39:279-87.
15. Hay WW, Brockway JM, Eyzaguirre M. Neonatal pulse oximetry: accuracy and reliability. *Pediatrics* 1989;83:717-22.
16. Levene S, Lear GH, McKenzie SA. Comparison of pulse oximeters in healthy sleeping infants. *Respir Med* 1989;83:233-5.
17. Thilo EJ, Andersen D, Wasserstein ML, Schmidt J, Luckey D. Saturation by pulse oximetry: comparison of the results obtained by instruments of different brands. *J Pediatr* 1993;122:620-6.
18. Poets CF, Stebbans VA, Southall DP. Arterial oxygen saturation and breathing movements during the first year of life. *J Dev Physiol* 1991;15:341-5.
19. Poets CF. When do infants need additional inspired oxygen? A review of the current literature. *Pediatr Pulmonol* 1998;26:424-8.

## *50 Years Ago in The Journal of Pediatrics*

### MYCOTIC INFECTIONS IN CHILDREN (THE BUDDING YEASTS AS AGENTS OF DISEASE)

*Clinical Conference, Taylor G (Conference Chairman). J Pediatr 1949;35:385-9*

In this article faculty from the Departments of Pediatrics and Bacteriology at Duke University School of Medicine discuss the epidemiology, clinical manifestations, microbiologic distinction, and treatment of mucosal and systemic infections caused by budding yeasts. Histoplasmosis, with a preponderance of cases in the Mississippi Valley, and North American blastomycosis, with limitation to the North American continent, were the major focus of the article because of their relatively high incidence and unique geographic occurrence. Candidiasis and cryptococcosis, although widespread geographically, were rarely serious infections in 1949. Treatments for fungal disease were limited to potassium iodide and gentian violet (sometimes given parenterally).

Fast forward to 1999. Unfortunately, healthy children continue to have, albeit rarely, histoplasmosis (except in the Mississippi Valley where it occurs frequently) and blastomycosis, but more effective treatments are available. Candidiasis, on the other hand—in current settings of immunosuppressive diseases or treatments, use of broad-spectrum and potent antibiotics, and invasive devices—has become *the* infectious disease of the decade. Although the shelf space and dollars required to stock the variety of available antifungal agents in hospital pharmacies today are greater, effectiveness of treatment is still highly dependent on removing the fungal foe's advantage—by reconstituting immune competence, removing catheters, and avoiding antibiotics.

*Sarah S. Long, MD  
Section of Infectious Diseases  
St Christopher's Hospital for Children  
Philadelphia, PA 19134-1095*